FrancophonIA/ELRC3.0 huggingface dataset:
English: Suvaxyn CSF Marker is a recombinant veterinary vaccine that contains live bovine viral diarrhoea virus (BVDV) which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of classical swine fever virus (CSFV).
Estonian: Suvaxyn CSF Marker on rekombinantne veterinaarvaktsiin, mis sisaldab veiste viirusdiarröa elusviirust (BVDV), mida on muudetud, et asendada BVDV ümbrise geen (E2) sigade klassikalise katku viiruse (CSFV) vastava geeniga.
English: The field study showed that vaccination with Suvaxyn CSF Marker resulted in 19 out of 20 piglets developing antibodies against E2 protein.
Estonian: Väliuuring tõendas, et Suvaxyn CSF Markeriga vaktsineerimise tulemusel tekkisid valgu E2 vastu antikehad 19 põrsal 20st.
English: Suvaxyn CSF Marker is used to protect pigs against outbreaks of classical swine fever, a very severe and highly contagious viral disease of both wild and domestic pigs.
Estonian: Suvaxyn CSF Markerit kasutatakse sigade kaitsmiseks sigade klassikalise katku puhangute eest; sigade klassikaline katk on väga raske ja äärmiselt nakkav mets- ja kodusigade viirushaigus.
English: This is because if given to pregnant sows it does not prevent them from passing CSFV infection to their offspring but can hide signs of infection in the piglets, allowing them to spread the disease.
Estonian: Vaktsiin ei takista tiinetel emistel andmast CSFV-infektsiooni edasi põrsastele, vaid võib põrsastel varjata infektsiooni sümptomeid, mistõttu nad võivad haigust levitada.
English: The vaccine is given to pigs from seven weeks of age as a single injection into the muscle.
Estonian: Vaktsiiniannus manustatakse intramuskulaarselt ühekordse süstina vähemalt 7-nädalastele sigadele.
English: There are no known side effects with Suvaxyn CSF Marker when it is used according to the approved indication of the product information.
Estonian: Suvaxyn CSF Markeril ei ole teadaolevaid kõrvalnähte, kui seda kasutatakse ravimiteabes heaks kiidetud näidustusel.
English: When the vaccine is given to a healthy pig, the animal's immune system recognises the vaccine virus as ‘foreign' and makes antibodies against it.
Estonian: Kui vaktsiini manustatakse tervele seale, peab looma immuunsüsteem vaktsiiniviirust võõraks ja tekitab selle vastu antikehi.
English: What is Suvaxyn CSF Marker?
Estonian: Mis on Suvaxyn CSF Marker?
English: Why has Suvaxyn CSF Marker been approved?
Estonian: Miks Suvaxyn CSF Marker heaks kiideti?
English: Other information about Suvaxyn CSF Marker:
Estonian: Muu teave Suvaxyn CSF Markeri kohta
English: What is the risk associated with Suvaxyn CSF Marker?
Estonian: Mis riskid Suvaxyn CSF Markeriga kaasnevad?
English: How has Suvaxyn CSF Marker been studied?
Estonian: Kuidas Suvaxyn CSF Markerit uuriti?
English: What is Suvaxyn CSF Marker used for?
Estonian: Milleks Suvaxyn CSF Markerit kasutatakse?
English: How does Suvaxyn CSF Marker work?
Estonian: Kuidas Suvaxyn CSF Marker toimib?
English: What benefit has Suvaxyn CSF Marker shown during the studies?
Estonian: Milles seisneb uuringute põhjal Suvaxyn CSF Markeri kasulikkus?
English: The application was submitted in the framework of Article 32 of Directive 2001/82/EC, as amended, where the Reference Member State was the United Kingdom and the Concerned Member States were Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, The Netherlands, Portugal and Spain.
Estonian: Taotlus esitati muudetud direktiivi 2001/82/EÜ artikli 32 kohaselt; viiteliikmesriik oli Ühendkuningriik ning asjaomased liikmesriigid Austria, Belgia, Hispaania, Iirimaa, Itaalia, Kreeka, Madalmaad, Portugal, Prantsusmaa, Saksamaa ja Taani.
English: The Mutual Recognition Procedure started on 28 February
Estonian: Vastastikuse tunnustamise menetlus algas 28. veebruaril 2008.
English: The final opinion was converted into a Decision by the European Commission on 3 August 2009.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 3. augustil 2009.
English: 1 Article 33(4) of Directive 2001/82/EC, as amended.
Estonian: Muudetud direktiivi 2001/82/EÜ artikli 33 lõige 4.
English: The rapporteur and co-rapporteur appointed were: Dr Bruno Urbain and Dr Michael Holzhauser-Alberti, respectively.
Estonian: Ettekandjaks ja kaasettekandjaks määrati vastavalt dr Bruno Urbain ja dr Michael Holzhauser-Alberti.
English: Florfenicol is a synthetic broad spectrum antibiotic with a range of activity, including many Gramnegative and Gram-positive organisms.
Estonian: Florfenikool on laia spektriga sünteetiline antibiootikum, mille toime on mitmekesine, hõlmates paljusid gramnegatiivseid ja grampositiivseid organisme.
English: Ref. EMEA/313852/2009
Estonian: 3. august 2009 Viide: EMEA/562573/2009
English: Oral explanations were given on 16 April 2009.
Estonian: Suulised selgitused anti 16. aprillil 2009.
English: OPINION FOLLOWING AN ARTICLE 33 (4)1 REFERRAL FOR SHOTAFLOR 300 MG/ML SOLUTION FOR INJECTION FOR CATTLE International Non-Proprietary Name (INN): Florfenicol
Estonian: ARVAMUS PÄRAST ARTIKLI 33 LÕIKE 41 KOHAST ESILDIST, MIS KÄSITLEB RAVIMIT SHOTAFLOR 300 MG/ML SOLUTION FOR INJECTION FOR CATTLE Rahvusvaheline mittekaubanduslik nimetus (INN): florfenikool
English: Written explanations were provided by the Marketing Authorisation Holder on 15 January 2009.
Estonian: Müügiloa hoidja esitas kirjalikud selgitused 15. jaanuaril 2009.
English: Based on the evaluation of the rapporteurs' assessment of the currently available data, the CVMP considered that the use of the product as recommended for therapeutic use only does not constitute a risk for the environment.
Estonian: Kättesaadavate andmete ja ettekandjate hindamisaruannete põhjal leidis veterinaarravimite komitee, et ravimi kasutamine üksnes ravi jaoks soovitatud viisil ei tekita keskkonnale riski.
English: However, the CVMP also considered that the wording of the therapeutic indication as authorised in the Reference Member State should be amended to clearly state the limitations of the approved use and avoid incorrect interpretation.
Estonian: Inimravimite komitee leidis samuti, et viiteliikmesriigis heakskiidetud näidustust peab muutma ning see peab väljendama selgelt heakskiidetud kasutuse piire, et vältida vääriti tõlgendamist.
English: Therefore the Committee adopted an opinion on 14 May 2009 recommending the variation of the Marketing Authorisation in line with the proposed amendments to the Summary of Product Characteristics and package leaflet.
Estonian: Seetõttu võttis komitee 14. mail 2009 vastu arvamuse, milles soovitas anda ravimile muudetud müügiloa ning teha ravimi omaduste kokkuvõttesse ja pakendi infolehele soovitatud muudatused.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended Summary of Product Characteristics and package leaflet in the Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning muudetud ravimi omaduste kokkuvõte ja pakendi infoleht III lisas.
English: The Marketing Authorisation Holder, Virbac S.A., submitted an application via mutual recognition for Shotaflor 300 mg/ml solution for injection for cattle, on the basis of the marketing authorisation granted by the United Kingdom.
Estonian: Müügiloa hoidja, Virbac S.A., esitas Shotaflor 300 mg/ml süstelahus veistele müügiloa taotluse vastastikuse tunnustamise menetluse kaudu, võttes aluseks Ühendkuningriigis antud müügiloa.
English: Due to concerns raised by Germany and The Netherlands during the Mutual Recognition Procedure that Shotaflor 300 mg/ml solution for injection for cattle could present a potential serious risk to the environment, the United Kingdom referred the matter to the EMEA on 31 July 2008 under Article 33(4) of Directive 2001/82/EC.
Estonian: 31. juulil 2008 tegi Ühendkuningriik Euroopa Ravimiametile direktiivi 2001/82/EÜ artikli 33 lõike 4 kohase esildise Saksamaa ja Madalmaade tõstatatud probleemi tõttu,
English: DuoPlavin must not be used during the last three months of pregnancy.
Estonian: DuoPlavinit ei tohi kasutada kolmel viimasel raseduskuul.
English: The European Commission granted a marketing authorisation valid throughout the EU for DuoPlavin on 15 March 2010.
Estonian: Euroopa Komisjon andis DuoPlavini müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. märtsil
English: The full EPAR for DuoPlavin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst DuoPlavini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It also presented the results of 3 previous studies involving over 61,000 patients with unstable angina or who had had a heart attack.
Estonian: Samuti esitati tulemused kolmest varasemast uuringust, kus osales üle 61 000 patsiendi, kellel oli ebastabiilne stenokardia või oli olnud südameinfarkt.
English: It is available as tablets containing 75 mg clopidogrel, either with 75 mg or 100 mg acetylsalicylic acid.
Estonian: Seda turustatakse tablettidena, mis sisaldavad 75 mg klopidogreeli koos 75 mg või 100 mg atsetüülsalitsüülhappega.
English: Acetylsalicylic acid has been available for over 100 years.
Estonian: Atsetüülsalitsüülhapet on turustatud üle 100 aasta.
English: The Committee therefore decided that DuoPlavin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas seetõttu, et DuoPlavini kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Clopidogrel has been authorised since 1998 for reducing platelet aggregation, and is often used in combination with acetylsalicylic acid.
Estonian: Klopidogreelil on alates 1998. aastast müügiluba trombotsüütide agregatsiooni vähendamiseks ning seda kasutatakse sageli koos atsetüülsalitsüülhappega.
English: Because the two active substances have been used together for a number of years, the company presented the results of studies showing that the active substances in DuoPlavin are absorbed in the body in the same way when taken in a single tablet as when the two medicines are taken separately.
Estonian: Et mõlemat toimeainet on koos kasutatud aastaid, esitas ettevõte uuringute tulemused, mis näitavad, et DuoPlavini toimeained absorbeeruvad organismis ühe tabletina samal viisil kui ravimid eraldi võetuna.
English: This document is a summary of the European Public Assessment Report (EPAR) for DuoPlavin.
Estonian: See on ravimi DuoPlavin Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with DuoPlavin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate DuoPlaviniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: DuoPlavin clopidogrel / acetylsalicylic acid
Estonian: DuoPlavin klopidogreel/atsetüülsalitsüülhape
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DuoPlavin.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Other information about DuoPlavin:
Estonian: Muu teave DuoPlavini kohta
English: What is the risk associated with DuoPlavin?
Estonian: Mis riskid DuoPlaviniga kaasnevad?
English: The most common side effects with DuoPlavin (seen in between 1 and 10 patients in 100) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured.
Estonian: DuoPlavini kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on hematoom (verimuhk), epistaksis (ninaverejooks), gastrointestinaalne hemorraagia (mao- või sooleverejooks), kõhulahtisus, kõhuvalu, düspepsia (kõrvetised), verevalumid ja süstekoha veritsus.
English: Why has DuoPlavin been approved?
Estonian: Miks DuoPlavin heaks kiideti?
English: • patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from thrombolytic treatment (treatment to dissolve blood clots).
Estonian: • patsiendid, kellel ravitakse ST-segmendi elevatsiooniga südameinfarkti, kui arsti arvates oleks trombolüütiline (soonesiseseid verehüübeid lahustav) ravi neile soodne.
English: DuoPlavin is a medicine that contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin).
Estonian: DuoPlavin on ravim, mis sisaldab kaht toimeainet, klopidogreeli ja atsetüülsalitsüülhapet (aspiriini).
English: For the full list of all side effects reported with DuoPlavin, see the package leaflet.
Estonian: DuoPlavini kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The combination of the two active substances has an additive effect, reducing the risk of blood clots forming, more than either medicine alone.
Estonian: Kahe toimeaine kombinatsioonil on aditiivne efekt, mis vähendab trombide tekke riski rohkem kui kumbki ravim eraldi.
English: The CHMP noted that DuoPlavin is comparable to clopidogrel and acetylsalicylic acid tablets taken separately, and concluded that combining both active substances in a single DuoPlavin tablet simplifies treatment for patients as they will need to take fewer tablets.
Estonian: Inimravimite komitee märkis, et DuoPlavin on võrreldav klopidogreeli ja atsetüülsalitsüülhappe eraldi võetavate tablettidega, ning järeldas, et mõlemat toimeainet sisaldav DuoPlavini tablett lihtsustab patsientide jaoks raviskeemi, sest nad peavad võtma vähem tablette.
English: Results from the 3 studies in patients with unstable angina or who had had a heart attack showed that the combination of clopidogrel and acetylsalicylic acid taken as separate tablets was more effective at preventing events such as heart attacks than acetylsalicylic acid alone.
Estonian: Ebastabiilse stenokardiaga või südameinfarkti üleelanud patsientidega korraldatud kolme uuringu tulemused näitasid, et eraldi tablettidena võetud klopidogreeli ja atsetüülsalitsüülhappe kombinatsioon oli selliste haigusjuhtude nagu südameinfarkti ennetamisel efektiivsem kui atsetüülsalitsüülhape eraldi.
English: • patients who have ‘unstable angina' (a severe type of chest pain) or who have had a heart attack with no ‘ST-segment elevation' (an abnormal reading on the ECG or electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up;
Estonian: • patsiendid, kellel on ebastabiilne stenokardia (teatud tugev rindkerevalu) või kellel on olnud STsegmendi elevatsioonita (teatud ebanormaalne EKG-näit) südameinfarkt, sealhulgas patsiendid, kellel paigaldatakse arterisse stent (lühike toru, mis takistab soone sulgumist);
English: It must not be used in patients who have a disease that is causing bleeding, such as stomach ulcer or bleeding in the brain or in patients with mastocytosis (high blood levels of certain white blood cells called mast cells).
Estonian: DuoPlavinit ei tohi kasutada patsiendid, kellel on verejookse põhjustav haigus, näiteks maohaavand või ajuverejooks, ega patsiendid, kellel on mastotsütoos (teatud valgeliblede ehk nuumrakkude suur sisaldus veres).
English: DuoPlavin is used to prevent problems caused by blood clots and hardening of the arteries, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid as separate tablets.
Estonian: DuoPlavinit kasutatakse trombide ehk soonesiseste verehüüvete moodustumisest ja arterite lubjastumisest põhjustatud probleemide, näiteks infarkti ennetamiseks täiskasvanutel, kes juba võtavad nii klopidogreeli kui ka atsetüülsalitsüülhapet eraldi tablettidena.
English: It can be used in the following groups of patients who have a condition known as ‘acute coronary syndrome':
Estonian: Ravimit tohib kasutada järgmistel ägeda koronaarsündroomiga patsiendirühmadel:
English: DuoPlavin was shown to be comparable to clopidogrel and acetylsalicylic acid taken separately, and can therefore be used in place of the clopidogrel and acetylsalicylic acid tablets that the patients have already been taking.
Estonian: Uuringud osutasid, et DuoPlavini toime on võrreldav eraldi võetud klopidogreeli ja atsetüülsalitsüülhappe toimega ning ravimit saab seetõttu kasutada klopidogreeli ja atsetüülsalitsüülhappe eraldi võetavate tablettide asemel, mida patsient on seni kasutanud.
English: DuoPlavin is taken as one tablet once a day in place of the clopidogrel and acetylsalicylic acid tablets that the patient has already been taking separately.
Estonian: DuoPlavinit võetakse üks tablett üks kord ööpäevas seni eraldi võetud klopidogreeli ja atsetüülsalitsüülhappe tablettide asemel.
English: What benefit has DuoPlavin shown during the studies?
Estonian: Milles seisneb uuringute põhjal DuoPlavini kasulikkus?
English: How does DuoPlavin work?
Estonian: Kuidas DuoPlavin toimib?
English: Acetylsalicylic acid stops the platelets sticking together by blocking an enzyme called prostaglandin cyclo-oxygenase.
Estonian: Atsetüülsalitsüülhape peatab trombotsüütide kokkukleepumise, blokeerides ensüümi prostaglandiintsüklooksügenaasi.
English: Clopidogrel stops the platelets sticking together by blocking a substance called ADP from attaching to a special receptor on their surface.
Estonian: Klopidogreel peatab trombotsüütide kokkukleepumise, takistades adenosiindifosfaati seondumist teatud retseptoriga trombotsüütide pinnal.
English: DuoPlavin must not be used in people who are hypersensitive (allergic) to clopidogrel, non steroidal anti-inflammatory drugs (such as acetylsalicylic acid) or any of the other ingredients in DuoPlavin.
Estonian: DuoPlavinit ei tohi kasutada patsiendid, kes on klopidogreeli, mittesteroidsete põletikuvastaste ainete (NSAID, nt atsetüülsalitsüülhappe) või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: What is DuoPlavin used for?
Estonian: Milleks DuoPlavinit kasutatakse?
English: How is DuoPlavin used?
Estonian: Kuidas DuoPlavinit kasutatakse?
English: It must not be used in patients who have severely reduced liver or kidney function, or who have a medical condition that includes a combination of asthma, rhinitis (stuffy and runny nose) and nasal polyps (growths in the lining of the nose).
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on raske maksa- või neerupuudulikkus või meditsiiniseisund, millega kaasneb astma, riniidi (ninakinnisus ja ninavoolus)
English: How has DuoPlavin been studied?
Estonian: Kuidas DuoPlavinit uuriti?
English: This reduces the production of a substance called thromboxane, which normally helps clots to form by attaching platelets together.
Estonian: See vähendab verehüüvete moodustumisel trombotsüüte siduva aine tromboksaani teket.
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming.
Estonian: See vähendab trombotsüütide kokkukleepumist ja verehüüvete tekke riski.
English: Both active substances in DuoPlavin, clopidogrel and acetylsalicylic acid, are antiplatelet medicines.
Estonian: DuoPlavini mõlemad toimeained, klopidogreel ja atsetüülsalitsüülhape, on trombotsüütide agregatsiooni vastased ravimid, mis aitavad ennetada trombotsüütide kokkukleepumist ja trombide teket ja hoida ära järgmist südameinfarkti.
English: The medicine can only be obtained with a prescription.
Estonian: DuoPlavin on retseptiravim.
English: What measures are being taken to ensure the safe and effective use of Pelmeg?
Estonian: Mis meetmed võetakse, et tagada Pelmegi ohutu ja efektiivne kasutamine?
English: Further information on Pelmeg can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/pelmeg.
Estonian: Lisateave Pelmegi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/pelmeg.
English: What is Pelmeg and what is it used for?
Estonian: Mis on Pelmeg ja milleks seda kasutatakse?
English: Other information about Pelmeg
Estonian: Muu teave Pelmegi kohta
English: This means that Pelmeg is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Estonian: See tähendab, et Pelmeg on väga sarnane teise bioloogilise ravimiga (võrdlusravimiga), millel juba on ELis müügiluba.
English: As for all medicines, data on the use of Pelmeg are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Pelmegi kasutamise kohta pidevat järelevalvet.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Pelmeg has a highly similar structure, purity and biological activity to Neulasta and is distributed in the body in the same way.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt ELi nõuetele bioloogiliselt sarnaste ravimite kohta on Pelmeg struktuuri, puhtuse ja bioloogilise toime poolest väga sarnane Neulastaga ning jaotub organismis samamoodi.
English: How is Pelmeg used?
Estonian: Kuidas Pelmegit kasutatakse?
English: Side effects reported with Pelmeg are carefully evaluated and any necessary action taken to protect patients.
Estonian: Pelmegi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Therefore, the Agency's view was that, as for Neulasta, the benefit of Pelmeg outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Neulasta korral, ületab Pelmegi kasulikkus sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: For more information about using Pelmeg, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Pelmegi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: What are the risks associated with Pelmeg?
Estonian: Mis riskid Pelmegiga kaasnevad?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pelmeg have been included in the summary of product characteristics and the package leaflet.
Estonian: Pelmegi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The safety of Pelmeg has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Neulasta.
Estonian: Pelmegi ohutust on hinnatud ja kõigi uuringute põhjal peetakse ravimi kõrvalnähte võrreldavaks võrdlusravimi Neulasta kõrvlanähtudega.
English: The most common side effect with Pelmeg (which may affect more than 1 in 10 people) is pain in the bones.
Estonian: Pelmegi kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on luuvalu.
English: The active substance in Pelmeg, pegfilgrastim, is a form of filgrastim, which is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).
Estonian: Pelmegi toimeaine pegfilgrastiim on filgrastiimi vorm, mis on väga sarnane teatud inimvalgugagranulotsüütide kolooniaid stimuleeriva faktoriga (G-CSF).
English: Because Pelmeg is a biosimilar medicine, the studies on effectiveness and safety of pegfilgrastim carried out with Neulasta do not all need to be repeated for Pelmeg.
Estonian: Et Pelmeg on bioloogiliselt sarnane ravim, ei pea Neulastaga tehtud pegfilgrastiimi efektiivsus- ja ohutusuuringuid Pelmegiga kordama.
English: Pelmeg is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines).
Estonian: Pelmegit manustatakse annuses 6 mg ühekordse subkutaanse süstena vähemalt 24 tundi pärast iga keemiaravitsükli (vähi ravimravi) lõppu.